Disease · MONDO_0007959
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Average-Risk Group vs High-Risk Group: serious adverse events | 17 of 269 | 17 of 144 | 413 | NCT00085202 | Trial comparisons |
| Arm I (Temozolomide, Irinotecan Hydrochloride) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Bevacizumab): deaths from any cause | 48 of 54 | 42 of 52 | 106 | NCT01217437 | Trial comparisons |
| Arm I (Temozolomide, Irinotecan Hydrochloride) vs Arm II (Temozolomide, Irinotecan Hydrochloride, Bevacizumab): serious adverse events | 9 of 54 | 12 of 52 | 106 | NCT01217437 | Trial comparisons |
| Temozolomide + Irinotecan for Medulloblastoma vs Temozolomide + Irinotecan for High-Grade Glioma: serious adverse events | 31 of 66 | 5 of 17 | 83 | NCT00404495 | Trial comparisons |
Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism | 3 of 39 | 5 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Low Somatomedin C | 2 of 39 | 5 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Secondary Malignancies | 1 of 39 | 0 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Diabetes Insipidus | 1 of 39 | 1 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): deaths from any cause | 18 of 39 | 15 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): Number of Participants With Chronic Central Hypothyroidism | 1 of 39 | 1 of 38 | 77 | NCT00336024 | Trial comparisons |
| Arm I (Patients Treated Without Methotrexate (MTX)) vs Arm II (Patients Treated With MTX): serious adverse events | 8 of 39 | 3 of 38 | 77 | NCT00336024 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan | 1 of 1 | 20 of 27 | 28 | NCT00602667 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan | 0 of 1 | 8 of 27 | 28 | NCT00602667 | Trial comparisons |
| Dose Level 1 vs Dose Level 2: serious adverse events | 1 of 6 | 1 of 6 | 12 | NCT00993044 | Trial comparisons |
| 10 mCi 177Lu-DTPA-omburtamab vs 25 mCi 177Lu-DTPA-omburtamab: Dose Limiting Toxicities (DLTs) Part 1 | 0 of 1 | 1 of 1 | 2 | NCT04167618 | Trial comparisons |
| 10 mCi 177Lu-DTPA-omburtamab vs 25 mCi 177Lu-DTPA-omburtamab: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT04167618 | Trial comparisons |
| 10 mCi 177Lu-DTPA-omburtamab vs 25 mCi 177Lu-DTPA-omburtamab: serious adverse events | 1 of 1 | 0 of 1 | 2 | NCT04167618 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007959/comparisons